Jump to main content
eTG Complete
eTG Complete
Index
  1. Home
  2. Addiction
  3. Volatile inhalants: hazardous, harmful and dependent use
  4. Withdrawal management in disorders of volatile inhalant use
  • Addiction
    • What is covered in the Addiction guidelines?
    • Overview of substance use and addictive behaviours
    • Tobacco smoking and nicotine dependence
    • Alcohol: hazardous, harmful and dependent use
    • Opioids: hazardous, harmful and dependent use
    • Benzodiazepines, zolpidem and zopiclone: hazardous, harmful and dependent use
    • Cannabis: hazardous, harmful and dependent use
    • Gamma-hydroxybutyrate (GHB): hazardous, harmful and dependent use
    • Hallucinogens: hazardous and harmful use
    • Ketamine: hazardous and harmful use
    • Pregabalin and gabapentin: hazardous, harmful and dependent use
    • Quetiapine and other antipsychotics: hazardous, harmful and dependent use
    • Sedating antihistamines: hazardous, harmful and dependent use
    • Stimulants: hazardous, harmful and dependent use
    • Volatile inhalants: hazardous, harmful and dependent use
      • Overview of disorders of volatile inhalant use
      • Screening and assessment of volatile inhalant use
      • Overview of management of disorders of volatile inhalant use
      • Harm reduction in volatile inhalant use
      • Withdrawal management in disorders of volatile inhalant use
      • Long-term care in the management of disorders of volatile inhalant use
      • Further educational resources for healthcare professionals about volatile inhalant use
      • References
    • Addictive behaviours
    • Key resources for substance use and addictive behaviours

Withdrawal management in disorders of volatile inhalant use

Evidence to guide management of dependent inhalant use is very limited. If significant symptoms of moderate agitation occur on withdrawal, use verbal de-escalation and psychological interventions; seek specialist advice (eg from a clinical advisory service) if agitation persists. Offer patients who wish to stop using inhalants the supports outlined in Long-term care in the management of disorders of volatile inhalant use.

  • Contact us
  • Conditions of use and disclaimer
  • Privacy policy
  • Copyright permission
  • Support and FAQ

www.tg.org.au
All site content © Therapeutic Guidelines Limited 2020. Therapeutic Guidelines Limited, Ground Floor, 473 Victoria Street, West Melbourne, Victoria 3003, Australia © Therapeutic Guidelines Ltd (eTG August 2020)

Created: No created attribute found. Modified: No revised attribute found. (HW Diagnostics)